|[February 28, 2014]
Research and Markets: PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/zx8j9q/pharmapoint)
has announced the addition of the "PharmaPoint:
Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022"
report to their offering.
HCV Market Is Expected to Grow During the Forecast Period
The HCV market generated approximately $4.0 billion from global sales in
2012. Over the next 10 years, this market is expected to grow to reach
$10.8 billion, with major growth occurring in the main HCV markets, such
as the US.
Some of the main drivers of growth are expected to be:
- Introduction of interferon-free HCV regimens, which have an improved
side effect profile compared with current HCV therapies
- Increase in patient awareness of HCV through screening initiatives and
public awareness campaigns
- A paradigm shift toward preventive care of HCV in most countries
The barriers limiting the growth of the market include:
- Limited patient awareness regarding the threat of HCV
- Concerns over decreasing healthcare costs as part of government
Pharma Giants Battle as New Entrants Leverage Next-Generation HCV
Regimens to Capture Market Share
Roche and Merck have been the HCV market leaders for the better part of
two decades. The companies leveraged their interferon and ribavirin
drugs to quickly capture market share. Roche's and Merck's commitment to
innovation resulted in the launch of peginterferon HCV therapies, which
quickly overtook the market, but bothcompanies fell behind in the race
to develop direct-acting antiviral (DAA) therapies for HCV.
This enabled Vertex (News - Alert) to establish itself as the leader in the US through
with the launch of Incivek (telaprevir). Janssen was also able to
capitalize on the demand for DAAs to become the front-runner in many
European markets through the launch of Incivo (telaprevir).
The authors anticipates that the launch of next-generation HCV regimens
will continue to enable new entrants, such as Gilead, AbbVie,
Bristol-Myers Squibb, and Boehringer Ingelheim, to capture market share.
Companies with interferon-free regimens are expected to quickly capture
market share in the US, Japan, and many European countries.
New Entrants Welcomed in the Market after the Launch of
Next-Generation HCV Regimens
There will still be demand for improved HCV therapies even after
next-generation HCV therapies have overtaken the market. Most late-stage
HCV regimens are focused on treating HCV genotype 1 infection since it
is the most prevalent strain, but there is demand for therapies with
pan-genotypic activity. A regimen that is well tolerated, effective
against all HCV genotypes, and requires less than 12 weeks of therapy
will likely steal patient share from the next-generation HCV therapies
that are included in this forecast.
Launch of Interferon-Free Regimens Will Fundamentally Change the HCV
Treatment Algorithm in the US, Japan, and Many European Countries
AbbVie's combination therapy (ABT-450, ABT-333, and ABT-267) is expected
to be among the first interferon-free HCV regimens to launch in several
countries. The regimen's tolerability, efficacy in both treatment-naïve
and treatment-experienced patients, and short duration of therapy are
expected to result in it becoming a front-line therapy. The authors
forecasts peak year sales for the regimen of $3.1 billion in 2018.
Gilead's fixed-dose, single-pill HCV regimen, sofosbuvir/ledipasvir, is
forecast to launch in most countries shortly after the first of the
interferon-free therapies. The ability of the sofosbuvir/ledipasvir
regimen to be safe and effective without co-administration with
ribavirin is expected to result in the drug becoming the standard of
care in many markets. The authors anticipates peak year sales for
sofosbuvir/ledipasvir of $4.3 billion in 2019.
Key Topics Covered:
1 Table of Contents
3 Disease Overview
5 Disease Management
6 Competitive Assessment
7 Opportunity and Unmet Need
8 Pipeline Assessment
9 Current and Future Players
10 Market Outlook
For more information visit http://www.researchandmarkets.com/research/zx8j9q/pharmapoint
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products.
[ Back To TMCnet.com's Homepage ]